Companies · Software / Tech

Allurion Technologies, Inc.

NATICK · Software / Tech · refined from filed group “Other Health Care

Diligence memoA one-page analyst read on Allurion Technologies, Inc. — recommendation, valuation, rhythm, risks.
$36.1M
Total raised · real
7
Rounds
0.7×
Latest step-up
Top 13%
Sector rank · raised
Series B
Latest stage · inferred · Fri Nov 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Allurion Technologies, Inc. looks under-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the technology sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.23× the median modeled value of Series B Software / Tech companies in 2025–2027 (95 peers) — value vs value, same stage and era.
Active
  • Last raise 8 mo ago; this sector typically re-raises about every 13 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Software / Tech

Allurion Technologies, Inc. is one of 3920 Software / Tech companies tracked from NATICK. By capital raised it ranks in the upper tier (ahead of 88% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
16
Investors (latest)
2023
Year incorporated
2025-11-14
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeed · 2012-07-12 Raised $1.7M (real) Modeled valuation $57M (est)Seed2012Seed · 2013-04-05 Raised $1.3M (real) Modeled valuation $43M (est)Seed2013Seed · 2014-07-15 Raised $1.6M (real) Modeled valuation $55M (est)Seed2014Series B · 2017-01-17 Raised $19M (real) Modeled valuation $579M (est)Series B2017Series B · 2023-12-18 Raised $123K (real) Modeled valuation $1.1M (est)Series B2023Series B · 2025-01-27 Raised $7.4M (real) Modeled valuation $45M (est)Series B2025Series B · 2025-11-14 Raised $5.0M (real) Modeled valuation $23M (est)Series B2025+$1.3M+$1.6M+$19M+$123K+$7.4M+$5.0MCumulative $36M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.7M · 2012
Seed extension$1.3M · 2013
Seed extension$1.6M · 2014
Series B$19.0M · 2017no Series A on file
Series B extension$123K · 2023
Series B extension$7.4M · 2025
Series B extension$5.0M · 2025

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$23.1M
Base estimate est.
$12.3M
Conservative case
$31.8M
Upside case
$27.8M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the technology sector profile. Directional, not a quoted figure.

Seed · modeled $56.5M · 2012-07-122012Seed · modeled $42.6M · 2013-04-05Seed · modeled $55.2M · 2014-07-15Series B · modeled $579.3M · 2017-01-17Series B · modeled $1.1M · 2023-12-18Series B · modeled $45.4M · 2025-01-27Series B · modeled $23.1M · 2025-11-142025
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
67%
Survival probability
44% low · 81% high
1.42×/yr
Annual markup
1.72×/yr upside case
0.6 yr
Elapsed time used
0.6 yr actual, capped for stale marks
technology
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
27 mo
Avg between rounds
$2.7M/yr
Capital velocity
14.0 yr
On record since
2012
First round
7
Rounds on file
How it compares to the market

Benchmarked against 3920 companies in Software / Tech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 7.9× above median
This company$36.1M
Sector median$4.6M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.3× of median
This company$5.0M
Sector median$19.9M
Modeled value — vs sector median (estimate, all stages) 0.6× of median
This company$23.1M
Sector median$36.6M

Raised more than 88% of sector peers (real $). Modeled value above 42% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #83 of 95.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0M$100.0MCapital raised (log)Machina Labs, Inc. · Series B Raised $70.2M · modeled $205.6M (est)Metaview Technologies Inc. · Series B Raised $51.7M · modeled $198.0M (est)Felix Technologies Inc. · Series B Raised $61.1M · modeled $194.6M (est)Foxglove Technologies Inc. · Series B Raised $58.0M · modeled $190.8M (est)NetBox Labs, Inc. · Series B Raised $53.3M · modeled $184.8M (est)Omni Design Technologies, Inc. · Series B Raised $34.3M · modeled $182.7M (est)Alaffia Technology Solutions, Inc. · Series B Raised $57.3M · modeled $182.6M (est)Rivington Labs Inc. · Series B Raised $59.6M · modeled $176.4M (est)Labs Companies, Inc. · Series B Raised $57.5M · modeled $175.4M (est)Reveal Technology, Inc. · Series B Raised $28.5M · modeled $159.7M (est)Architect Financial Technologies Inc. · Series B Raised $52.5M · modeled $158.8M (est)Pylon Labs, Inc. · Series B Raised $49.7M · modeled $156.3M (est)Allurion Technologies, Inc. (this company) Raised $36.1M · modeled $23.1M (est)Allurion Technologies, Inc.
CompanyStageRaised · realValue · estvs peer med.
Machina Labs, Inc.Series B$70.2M$205.6M2.07×
Metaview Technologies Inc.Series B$51.7M$198.0M2.00×
Felix Technologies Inc.Series B$61.1M$194.6M1.96×
Foxglove Technologies Inc.Series B$58.0M$190.8M1.92×
NetBox Labs, Inc.Series B$53.3M$184.8M1.86×
Omni Design Technologies, Inc.Series B$34.3M$182.7M1.84×
Alaffia Technology Solutions, Inc.Series B$57.3M$182.6M1.84×
Rivington Labs Inc.Series B$59.6M$176.4M1.78×
Labs Companies, Inc.Series B$57.5M$175.4M1.77×
Reveal Technology, Inc.Series B$28.5M$159.7M1.61×
Architect Financial Technologies Inc.Series B$52.5M$158.8M1.60×
Pylon Labs, Inc.Series B$49.7M$156.3M1.58×
Allurion Technologies, Inc. this companySeries B$36.1M$23.1M0.23×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.7M2012-07-12$8.3M$56.5M85%
Seed$1.3M2013-04-05$6.3M$42.6M85%
Seed$1.6M2014-07-15$8.1M$55.2M85%
Series B$19.0M2017-01-17$105.7M$579.3M90%
Series B$123K2023-12-18$681K$1.1M90%
Series B$7.4M2025-01-27$41.3M$45.4M90%
Series B$5.0M2025-11-14$27.8M$23.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.7M2012-07-12
    • First recorded raise — entered as Seed.
    • 25 investors on this round.
  2. Seed$1.3M2013-04-05
    • Raised 9 mo later, in step with the ~13 mo sector norm.
    • Round 1.3× smaller than the prior — bridge or down round.
    • 25 investors on this round.
  3. Seed$1.6M2014-07-15
    • Raised 15 mo later, in step with the ~13 mo sector norm.
    • Round roughly the size of the prior one.
    • Switched to Rule 506(b) (was Rule 06).
    • 21 investors on this round.
  4. Series B$19.0M2017-01-17
    • Raised again after 30 mo — slower than the ~13 mo sector norm.
    • Round 11.7× larger than the prior — scaling up.
    • 45 investors on this round.
  5. Series B$123K2023-12-18
    • Raised again after 83 mo — slower than the ~13 mo sector norm.
    • Round 155.3× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  6. Series B$7.4M2025-01-27
    • Raised 13 mo later, in step with the ~13 mo sector norm.
    • Round 60.7× larger than the prior — scaling up.
    • 14 investors on this round.
  7. Series B$5.0M2025-11-14
    • Raised 10 mo later, in step with the ~13 mo sector norm.
    • Round 1.5× smaller than the prior — bridge or down round.
    • 16 investors on this round.
Intelligence
2028 ~Q1
Modeled next raise · ~27mo cadence
$5.0M
Modeled next size est.range $5.0M$8.0M
0.7×
Last step-up
$2.7M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Krishna Gupta8 other2025-01
Larson Douglas Hudson2 other2025-01
Michael Davin1 other2025-01
Omar Ishrak1 other2025-01
Benoit Jacques Claude Chardon2023-12
Brendan Gibbons2025-01
Chris Geberth2023-12
Douglas Hudson Larson2023-12
Jonathan D Wecker2012-07
Keith Douglas Johns2025-01
Krishna D Gupta2017-01
Krishna Jacques Claude Gupta2023-12
Michael Jacques Claude Davin2023-12
Milena Douglas Alberti-Perez2025-01
Neil D Chheda2017-01
Nicholas Douglas Lewin2025-01
Nicholas Hudson Lewin2023-12
Ojas Buch2025-01
Omar Jacques Claude Ishrak2023-12
Ram Chuttani2012-07
R. Jason Douglas Richey2025-01
Samuel G Levy2012-07
Shantanu Gaur2023-12
Shantanu K Gaur2012-07
Registry & provenance

Allurion Technologies, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1554851
SEC CIK
2023
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
CMS Technology, Inc.Software / TechSeries B$35.9M$28.9Msame sector · same stage
Upshot Technologies, Inc.Software / TechSeries B$34.8M$22.8Msame sector · same stage
Redica Systems, Inc.Software / TechSeries B$39.5M$27.9Msame sector · same stage
Prismatic Software Inc.Software / TechSeries B$30.7M$22.1Msame sector · same stage
LIS Technologies IncSoftware / TechSeries B$64.5M$28.7Msame sector · same stage
Presto Phoenix, Inc.Other TechnologySeries B$28.0M$44.4Mnetwork1 shared operator · same stage
Matrix Analytics, Inc.Software / TechSeries B$19.7M$26.4Msame sector · same stage
NoHo Wellness, Inc.HealthtechSeries B$27.2M$474.3Mnetwork1 shared operator · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Jaxon Technologies, LLCSoftware / TechSeries A$144.2M84%
Allora Health Inc.HealthtechSeries A$38.5M83%
Revon Systems, Inc.Software / TechSeed$15.5M82%
samark technology CorpSoftware / TechPre-Seed$4.2M82%
SomnoMed Technologies Inc.Software / TechPre-Seed$3.7M82%
Limerick Technologies, Inc.Software / TechPre-Seed$2.3M82%
InterShunt Technologies, Inc.Software / TechSeries B$168.5M82%
NeuX Technologies, Inc.Software / TechSeed$51.1M82%
Frequently asked
How much funding has Allurion Technologies, Inc. raised?
Allurion Technologies, Inc. has raised approximately $36.1M in disclosed capital across 7 recorded financing rounds, aggregated from public filings.
What is Allurion Technologies, Inc.'s estimated valuation?
Provath's modeled valuation for Allurion Technologies, Inc. is approximately $23.1M (modeled range $12.3M–$31.8M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Allurion Technologies, Inc. at?
Allurion Technologies, Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Fri Nov 14.
What does Allurion Technologies, Inc. do and where is it based?
Allurion Technologies, Inc. operates in the Software / Tech sector, based in NATICK.
Explore related

See where Allurion Technologies, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Allurion Technologies, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.